Clinical Trials Logo

Sarcoma, Soft Tissue clinical trials

View clinical trials related to Sarcoma, Soft Tissue.

Filter by:

NCT ID: NCT00297258 Completed - Clinical trials for Sarcoma, Soft Tissue

Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma

Start date: November 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the activity and tolerability of pazopanib in subjects with advanced and/or metastatic soft tissue sarcoma who have relapsed following standard therapies or for whom no standard therapy exists and to characterize the pharmacokinetics of pazopanib in this subject population.

NCT ID: NCT00289809 Completed - Clinical trials for Sarcoma, Soft Tissue

TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients

Start date: September 2006
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose of the TLC D-99 combined with ifosfamide and then the efficacy of this combination in terms of overall response rate, time to progression and time of response

NCT ID: NCT00243685 Completed - Breast Neoplasms Clinical Trials

Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis

Start date: September 2006
Phase: Phase 2/Phase 3
Study type: Interventional

DiaTech is a private company performing patient specific cancer chemosensitivity testing for patients and physicians. DiaTech Oncology is doing this clinical study to see if an experimental new technology called the microculture kinetic (MiCK) assay will predict treatment outcome and can help to direct the chemotherapy of cancer subjects. This study is focused on subjects diagnosed with breast, ovarian, lung, and colon malignancies and low-grade lymphomas. Study Objectives: - To evaluate the ability of the MiCK assay to predict the outcome of chemotherapy of cancer patients. - To evaluate the ability of the MiCK assay to guide chemotherapy of cancer patients.

NCT ID: NCT00204646 Completed - Clinical trials for Sarcoma, Soft Tissue

Neoadjuvant Adriamycin and Ifosfamide Plus High-Dose ICE in Patients With Soft Tissue Sarcoma (STS)

Start date: February 1999
Phase: Phase 2
Study type: Interventional

Complete resection is still the only curative treatment option in patients with soft tissue sarcoma (STS). Patients with a non-resectable STS have a dismal prognosis even without evidence of metastatic disease. The aim of this trial is to determine whether neoadjuvant dose-intensive chemo-radiotherapy is a feasible and effective approach in patients with non-resectable STS.

NCT ID: NCT00204620 Completed - Clinical trials for Sarcoma, Soft Tissue

Bendamustin Hydrochloride in Patients With Soft Tissue Sarcoma (STS)

Start date: March 2002
Phase: Phase 2
Study type: Interventional

The aims of this trial are to evaluate the efficacy of bendamustin in patients with metastatic soft tissue sarcoma who have progressed after or during an anthracycline-baesd chemotherapy and to assess the treatment of toxicity.

NCT ID: NCT00189137 Completed - Clinical trials for Sarcoma, Soft Tissue

Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

Start date: August 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to explore how a sarcoma is affected by and the side effects of a newer combination of chemotherapy drugs(gemcitabine and docetaxel)as compared to a standard combination of chemotherapy drugs, ifosfamide and doxorubicin.

NCT ID: NCT00187174 Completed - Tumors Clinical Trials

Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

Start date: October 2004
Phase: Phase 1
Study type: Interventional

Patients with recurrent or refractory solid tumors or brain tumors that are unresponsive to conventional therapy, or with no known effective therapy, will be treated. Experiments in the laboratory have shown the experimental drug RAD001C (RAD001, Everolimus) can prevent cells from multiplying. RAD001 is now being tested in diseases such as cancer, in which excessive cell multiplication needs to be stopped. The drug has been tested in adult cancer patients and has been well tolerated by subjects in these studies. It is experimental and, therefore, available in clinical trials.

NCT ID: NCT00142571 Completed - Clinical trials for Sarcoma, Soft Tissue

Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma

Start date: January 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the drug gemcitabine to two drugs, gemcitabine and docetaxel, to find out which treatment is better for people with sarcomas.

NCT ID: NCT00134641 Completed - Clinical trials for Sarcoma, Soft Tissue

Study of Gemcitabine and Vinorelbine in Soft Tissue Sarcomas

Start date: February 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the combination of gemcitabine and vinorelbine is effective in treating patients with advanced soft tissue sarcoma.

NCT ID: NCT00130858 Completed - Clinical trials for Sarcoma, Soft Tissue

a Multicenter Clinical Trial for the Treatment of Children and Adolescents With Soft Tissue Sarcoma Stage 4

Start date: January 2005
Phase: Phase 2
Study type: Interventional

Phase II Study to evaluate the response on two blocks of topotecan and carboplatin